Perrigo Company plc (PRGO) is scheduled to report second-quarter 2024 numbers on Aug 2, before the opening bell. In the last reported quarter, the company posted an earnings surprise of 20.83%.Let’s see how things have shaped up for this announcement.Factors at PlayThe Zacks Consensus Estimate for Perrigo’s total revenues is pegged at around $1.13 billion, while the same for earnings stands at 48 cents per share. Both metrics indicate a decline from the year-ago quarter’s levels.Perrigo reports its results ...

The market expects Perrigo (PRGO) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on August 2, 2024, might help the stock move higher if these key numbers are better t ...

DUBLIN, July 19, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its second quarter 2024 financial results on Friday, August 2, 2024, and host a conference call beginning at 8:30 A.M. (EST).The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-664-6383, In ...

Core Viewpoint - Perrigo Company plc has completed the divestment of its HRA Pharma Rare Diseases business to Esteve Healthcare for a total consideration of up to €275 million, which includes an upfront cash payment of €190 million and potential earnout payments of up to €85 million based on sales milestones [1] Financial Impact - The HRA Pharma Rare Diseases business generated net sales of approximately €50 million and adjusted EBITDA of approximately €20 million in 2023 [1] - The proceeds from the divestment are expected to be redeployed for debt repayment [1] Transaction Details - The total consideration for the divestment is structured as an upfront cash payment of €190 million, subject to customary net debt and working capital adjustments, and up to €85 million in potential earnout payments [1] - The impact of this transaction was included in the Company's previously issued 2024 outlook [1]

SEATTLE, June 24, 2024 (GLOBE NEWSWIRE) -- UNITED STATES DISTRICT COURTDISTRICT OF NEW JERSEY ROOFER’S PENSION FUND, on behalf ofitself and all others similarly situated,                        Plaintiff,        v.JOSEPH C. PAPA, et al.,                        DefendantsCase No. 1:16-cv-02805-RMB-LDWCLASS ACTION SUMMARY NOTICE OF (I) PROPOSED SETTLEMENTAND PLAN OF ALLOCATION; (II) SETTLEMENT HEARING; AND(III) MOTION FOR ATTORNEYS’ FEES AND LITIGATION EXPENSES To:(1) All persons who purchased Perrigo Compan ...

It has been about a month since the last earnings report for Perrigo (PRGO) . Shares have lost about 15.1% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Perrigo due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Q1 Earnings Top, Sales Lag EstimatesPerrigo reporte ...

DUBLIN, May 28, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Oppenheimer 24th Annual Consumer Growth & E-Commerce Conference, being conducted virtually on Tuesday, June 11th at 1:30 PM EDT. Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts.About Perrigo Perrigo Comp ...

Have you evaluated the performance of Perrigo's (PRGO) international operations during the quarter that concluded in March 2024? Considering the extensive worldwide presence of this drug company, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influences its financial health and trajectory ...

Perrigo Company plc (NYSE:PRGO) Q1 2024 Earnings Call Transcript May 7, 2024 8:30 AM ET Company Participants Brad Joseph - VP, Global IR Patrick Lockwood-Taylor - President and CEO Eduardo Bezerra - CFO Conference Call Participants Susan Anderson - Canaccord Genuity Chris Schott - JPMorgan Daniel Biolsi - Hedgeye Operator Good morning, ladies and gentlemen, and welcome to Perrigo First Quarter 2024 Financial Results Conference Call. At this time, all lines are in listen-only mode. Following the presentation ...

Perrigo Company plc (PRGO) reported adjusted earnings of 29 cents per share in the first quarter of 2024, beating the Zacks Consensus Estimate of 24 cents. Earnings were down 35.6% year over year, primarily due to a negative financial impact of 30 cents per share from infant formula.Net sales declined 8.4% year over year to $1.08 billion, missing the Zacks Consensus Estimate of $1.09 billion. The downside was due to lower net sales in infant formula and the negative impact of purposeful SKU prioritization a ...